Search
Chiauranib
go.drugbank.com/drugs/DB16124InvestigationalChiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).
Telatinib
go.drugbank.com/drugs/DB15393InvestigationalTelatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).
Meningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Phosphoaminophosphonic Acid-Adenylate Ester
go.drugbank.com/drugs/DB04395ExperimentalAn analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom.
Bafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThese compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase).
Sitravatinib
go.drugbank.com/drugs/DB15036InvestigationalSitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalIt is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalThe growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. … Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials.
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.